|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
| Title: | Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting |
| Authors: | Atsumi, Tatsuya Browse this author →KAKEN DB | | Fujio, Keishi Browse this author →KAKEN DB | | Yamaoka, Kunihiro Browse this author | | Tomobe, Minako Browse this author | | Kuroyanagi, Kazuyuki Browse this author | | Kameda, Hideto Browse this author |
| Keywords: | Rheumatoid arthritis | | tocilizumab | | interleukin 6 | | postmarketing surveillance | | subcutaneous |
| Issue Date: | 2018 |
| Publisher: | Taylor & Francis |
| Journal Title: | Modern rheumatology |
| Volume: | 28 |
| Issue: | 5 |
| Start Page: | 780 |
| End Page: | 788 |
| Publisher DOI: | 10.1080/14397595.2017.1416760 |
| PMID: | 29251032 |
| Abstract: | Objectives: The objective of this study is to evaluate the safety and effectiveness of subcutaneous tocilizumab (TCZ-SC) in a real-world clinical setting in Japan.Methods: This single arm, 26-week prospective observational study enrolled patients with RA who were either TCZ naive or switched from TCZ-IV to TCZ-SC (TCZ-IV-SC group) (UMIN Clinical Trials Registry UMIN000011102). All patients received TCZ-SC 162mg every 2 weeks and data were collected until week 26 or discontinuation.Results: Overall 784 (78.1%) were TCZ naive and 219 (21.8%) were in the TCZ-IV-SC group. 70.9% received disease-modifying antirheumatic drugs at baseline. Adverse events (AEs) and serious AEs occurred in 28.2% and 4.9% of patients, respectively (TCZ-naive: 29.5% and 5.2%; TCZ-IV-SC: 23.2% and 4.1%). Infections and infestations were the most common AEs (7.4%) and serious AEs (1.7%). Two TCZ-naive patients died. TCZ-naive patients had an improvement in median Clinical Disease Activity Index (CDAI) score and mean Disease Activity Score in 28 joints as measured by erythrocyte sedimentation rate (DAS28-ESR) from baseline to week 26. The TCZ-IV-SC group had similar median CDAI scores and mean DAS28-ESR over 26 weeks.Conclusions: There were no unexpected safety signals with TCZ-SC. TCZ-SC was effective in reducing disease activity in TCZ-naive patients and maintaining remission in TCZ-IV-SC patients. |
| Rights: | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/72030 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 渥美 達也
|
